WikiJournalClub:List of landmark papers/Hematology

From Wiki Journal Club
Jump to: navigation, search


  • A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia [[1]]
  • Effective Treatment of Cobalamin Deficiency With Oral Cobalamin [[2]]
  • 2009 TREAT Darbepoetin in non-dialysis CKD and T2DM [[3]]



  • AMG 531 caused no major adverse events and increased platelet counts in patients with ITP. [[7]]
  • Eltrombopag increased platelet counts in a dose-dependent manner in patients with relapsed or refractory ITP [[8]]
  • Romiplostim increased and maintained platelet counts in splenectomised and non-splenectomised patients with ITP. [[9]]
  • Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura [[10]]
  • Heparin-induced thrombocytopenia can begin rapidly in patients who have received heparin within the previous 100 days. Heparin-dependent antibodies do not invariably reappear with subsequent heparin use. [[11]]
  • von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome [[12]]
  • 4 Ts for HIT pretest probability: criteria to estimate pretest probability of HIT [13]


  • Oral administration of phytonadione had similar efficacy and safety as intravenously administered phytonadione and may be suitable for treatment of patients with excessive anticoagulation. [[14]]
  • Low-dose oral vitamin K did not reduce bleeding in warfarin recipients with INRs of 4.5 to 10.0. [[15]]

DVT/PE and hypercoagulable states

  • CLOT: LMWH vs. coumadin for VTE among cancer patients
  • RE-COVER: Dabigatran vs. warfarin in VTE [16]
  • ASPIRE: Aspirin for prevention of recurrent VTE [17]

Antiphospholipid syndrome

  • High-intensity warfarin was not superior to moderate-intensity warfarin for thromboprophylaxis in patients with antiphospholipid antibodies and previous thrombosis. The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome. [[18]]
  • High-intensity warfarin was not superior to standard treatment in preventing recurrent thrombosis in patients with APS and was associated with an increased rate of minor hemorrhagic complications. [[19]]

Transfusion Therapy

  • TRICC Hb goal hemoglobin 7 versus 10 unless active cardiac ischemia NEJM 1999;340:409[20]
  • CCP Blood transfusion is associated with a lower short-term mortality rate among elderly patients with acute myocardial infarction if the hematocrit on admission is 30.0 percent or lower and may be effective in patients with a hematocrit as high as 33.0 percent on admission. [21]
  • Lenalidomide in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy. [22]

Polycythemia Vera

Acute Leukemia

  • In patients with AML who are older than 60 years of age, escalation of the dose of daunorubicin to twice the conventional dose, with the entire dose administered in the first induction cycle, effects a more rapid response and a higher response rate than does the conventional dose, without additional toxic effects. [25]
  • Intensifying induction therapy with a high daily dose of daunorubicin improved the rate of complete remission and the duration of overall survival, as compared with the standard dose.[26]
  • Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.[27]

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

  • IRIS After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. [[29]]
  • ENESTnd Nilotinib superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome–positive CML.[30]
  • Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia [[31]]
  • Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib.[[32]]
  • Nilotinib in imatinib-resistant CML.[[33]]
  • Fludarabine yields higher response rates and a longer duration of remission and progression-free survival than chlorambucil; overall survival is not enhanced.[[34]]
  • LRF CLL4 Fludarabine plus cyclophosphamide should now become the standard treatment for chronic lymphocytic leukaemia and the basis for new protocols that incorporate monoclonal antibodies. [[35]]
  • Although the presence of an unmutated IgVH gene is strongly associated with the expression of ZAP-70, ZAP-70 is a stronger predictor of the need for treatment in B-cell CLL. [[36]]
  • A unique microRNA signature is associated with prognostic factors and disease progression in CLL. Mutations in microRNA transcripts are common and may have functional importance. [[37]]


  • IPS score for Advanced Hodgkin's Disease [[38]]
  • CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma [[39]]
  • As compared with conventional chemotherapy, treatment with high-dose chemotherapy and autologous bone marrow transplantation increases event-free and overall survival in patients with chemotherapy-sensitive non-Hodgkin's lymphoma in relapse. [[40]]
  • A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial [[41]]
  • FLIPI Follicular Lymphoma International Prognostic Index [[42]]
  • The International Non-Hodgkin's Lymphoma Prognostic Factors Project [[43]]

Multiple Myeloma

  • The risk of progression from smoldering multiple myeloma to symptomatic disease is related to the proportion of bone marrow plasma cells and the serum monoclonal protein level at diagnosis. [[44]]
  • IFM 99—06 Use of thalidomide in combination with melphalan and prednisone for previously untreated elderly patients with multiple myeloma [[45]]
  • VISTA Bortezomib plus melphalan–prednisone was superior to melphalan–prednisone alone in patients with newly diagnosed myeloma who were ineligible for high-dose therapy [[46]]
  • Multiple Myeloma (010) Study Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma [[47]]
  • Multiple Myeloma (009) Study Lenalidomide plus dexamethasone is superior to placebo plus dexamethasone in patients with relapsed or refractory multiple myeloma. [[48]]
  • InterGroupe Francophone du Myélome As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation. [[49]]
  • When incorporated into high-dose therapy for myeloma, thalidomide increased the frequency of complete responses and extended event-free survival at the expense of added adverse effects without improving overall survival [[50]]
  • Myeloma Aredia Study Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma. [[51]]
  • 2012 EVOLUTION: CyBorD vs. VDR vs. VDCR in multiple myeloma

Sickle Cell Disease

  • 1995 MSH: Hydroxyurea in sickle cell disease [52]


  • The outcome of treatment of AL amyloidosis with high-dose melphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalan plus dexamethasone. [[53]]
  • Eprosidate promising for renal disease in AA [[54]]
  • Natural History and Outcome in Systemic AA Amyloidosis [[55]]